{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:28:52Z","timestamp":1790674132761,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.vhri.2017.03.012","type":"journal-article","created":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T03:45:28Z","timestamp":1501040728000},"page":"7-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective"],"prefix":"10.1016","volume":"13","author":[{"given":"Gihan Hamdy","family":"Elsisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa","family":"Aburawash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emam","family":"Waked","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2017.03.012_bib1","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/hep.21173","article-title":"Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors","volume":"43","author":"Strickland","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.vhri.2017.03.012_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ajg.2014.04.003","article-title":"The current and future disease burden of chronic hepatitis C virus infection in Egypt","volume":"15","author":"Waked","year":"2014","journal-title":"Arab J Gastroenterol"},{"key":"10.1016\/j.vhri.2017.03.012_bib3","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2893.2006.00823.x","article-title":"Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection","volume":"14","author":"Roulot","year":"2007","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.vhri.2017.03.012_bib4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jhep.2005.08.008","article-title":"Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections","volume":"44","author":"Deuffic-Burban","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.vhri.2017.03.012_bib5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/jmv.20414","article-title":"Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection","volume":"77","author":"Legrand-Abravanel","year":"2005","journal-title":"J Med Virol"},{"key":"10.1016\/j.vhri.2017.03.012_bib6","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1017\/S0266462312000463","article-title":"Shortened peginterferon and ribavirin treatment for chronic hepatitis C","volume":"28","author":"Hartwell","year":"2012","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.vhri.2017.03.012_bib7","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/apt.12601","article-title":"Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection","volume":"39","author":"Koff","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.vhri.2017.03.012_bib8","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vhri.2017.03.012_bib9","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.clinthera.2011.07.008","article-title":"Economic burden associated with patients diagnosed with hepatitis C","volume":"33","author":"McCombs","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.vhri.2017.03.012_bib10","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/apt.12625","article-title":"The impact of hepatitis C burden: an evidence-based approach","volume":"39","author":"Younossi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.vhri.2017.03.012_bib11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/apt.12871","article-title":"Cost-effectiveness analysis of sofosbuvir plus peginterferon\/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection","volume":"40","author":"Saab","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.vhri.2017.03.012_bib12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.7326\/M14-1152","article-title":"Cost-effectiveness of novel regimens for the treatment of hepatitis C virus","volume":"162","author":"Najafzadeh","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vhri.2017.03.012_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","article-title":"Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices\u2014Modeling Studies","volume":"6","author":"Weinstein","year":"2003","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2017.03.012_bib14","doi-asserted-by":"crossref","first-page":"e90295","DOI":"10.1371\/journal.pone.0090295","article-title":"Cost-effectiveness of telaprevir combination therapy for chronic hepatitis C","volume":"9","author":"Brogan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vhri.2017.03.012_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15170","article-title":"Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV\/HIV co-infection: a systematic review and economic evaluation","volume":"15","author":"Hartwell","year":"2011","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.vhri.2017.03.012_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.vhri.2013.06.014","article-title":"Recommendations for reporting pharmacoeconomic evaluations in Egypt","volume":"2","author":"Elsisi","year":"2013","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.vhri.2017.03.012_bib17","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/hep.23528","article-title":"Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis: a 12-year prospective follow-up study","volume":"51","author":"Bruno","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.vhri.2017.03.012_bib18","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1136\/gut.2003.038257","article-title":"Long-term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy","volume":"53","author":"Veldt","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.vhri.2017.03.012_bib19","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vhri.2017.03.012_bib20","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vhri.2017.03.012_bib21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/0003-4819-156-4-201202210-00005","article-title":"New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis","volume":"156","author":"Liu","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vhri.2017.03.012_bib22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vhri.2017.03.012_bib23","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vhri.2017.03.012_bib24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1440-1746.2011.06813.x","article-title":"Health utilities and psychometric quality of life in patients with early and late stage hepatitis C virus infection","volume":"27","author":"Hsu","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.vhri.2017.03.012_bib25","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s10198-014-0649-6","article-title":"Health state utilities associated with attributes of treatments for hepatitis C","volume":"16","author":"Matza","year":"2015","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.vhri.2017.03.012_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10210","article-title":"Health benefits of antiviral therapy for mild chronic hepatitis C: randomized controlled trial and economic evaluation","volume":"10","author":"Wright","year":"2006","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.vhri.2017.03.012_bib28","unstructured":"EconStats. IMF World Economic Outlook (WEO) data. Available from: http:\/\/www.econstats.com\/weo\/V013.htm. [Accessed July 24, 2017]."},{"key":"10.1016\/j.vhri.2017.03.012_bib29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS)\u2014explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2017.03.012_bib30","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"10.1016\/j.vhri.2017.03.012_bib31","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/jvh.12111","article-title":"All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses","volume":"20","author":"Hagan","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.vhri.2017.03.012_bib32","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jhep.2013.11.009","article-title":"Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients","volume":"60","author":"Younossi","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.vhri.2017.03.012_bib33","series-title":"Analysis of direct and indirect costs of HCV care with PEG-interferon triple therapy","author":"Sethi","year":"2013"},{"key":"10.1016\/j.vhri.2017.03.012_bib34","year":"2014","journal-title":"Recommendations for testing, managing, and treating hepatitis C"},{"key":"10.1016\/j.vhri.2017.03.012_bib35","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109917300468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109917300468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T02:04:30Z","timestamp":1535767470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109917300468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":34,"alternative-id":["S2212109917300468"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2017.03.012","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2017.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research (ISPOR).","name":"copyright","label":"Copyright"}]}}